- ►oxfordjournals.org [PDF] BK Edwards, ML Brown, PA Wingo, HL Howe, E … - JNCI Journal of the National Cancer Institute, 2005 - jnci.oxfordjournals.org Background: The American Cancer Society (ACS), the Cen- ters for Disease Control
and Prevention (CDC), the National Cancer Institute (NCI), and the North
American Association of Central Cancer Registries (NAACCR) collaborate ... Cited by 427 - Related articles - BL Direct - All 13 versions
- ►jcojournal.org OA O'Connor, J Wright, C Moskowitz, J Muzzy, … - Journal of Clinical Oncology, 2005 - jcojournal.org PATIENTS AND METHODS: Patients with indolent and MCL were eligible. Bortezomib
was given at a dose of 1.5 mg/m 2 on days 1, 4, 8, and 11. Patients were
required to have received no more than three prior chemotherapy regimens, ... Cited by 278 - Related articles - All 8 versions
JZ Ayanian, MB Landrum, E Guadagnoli, P … - The New England journal of medicine, 2002 - nejm.highwire.org ABSTRACT Background The outcome after myocardial infarc- tion may be influenced
by the type of physician pro- viding ambulatory care. Methods We studied 35,520
patients 65 years of age or older who were hospitalized for myocardial ... Cited by 124 - Related articles - BL Direct - All 5 versions
- ►ascopubs.org [PDF] JM Cragun, LJ Havrilesky, B Calingaert, I … - Journal of Clinical Oncology, 2005 - jco.ascopubs.org Purpose In randomized trials, patients with stage III colon cancer who received
6 months of fluorouracil (FU)-based adjuvant chemotherapy had better survival
than patients who did not. However, little is known about the predictors ... Cited by 123 - Related articles - All 10 versions
- ►nih.gov T Stürmer, M Joshi, RJ Glynn, J Avorn, KJ … - Journal of clinical epidemiology, 2006 - Elsevier Use of propensity scores increased from a total of 8 reports before 1998 to 71
in 2003. Most of the 177 published studies abstracted assessed medications (N =
60) or surgical interventions (N = 51), mainly in cardiology and cardiac ... Cited by 98 - Related articles - All 24 versions
JM McWilliams, AM Zaslavsky, E Meara, JZ … - JAMA, 2003 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context Uninsured adults ... Cited by 97 - Related articles - BL Direct - All 3 versions
- ►annals.org [PDF] R Viotti, C Vigliano, B Lococo, G Bertocchi, M … - Annals of internal medicine, 2006 - Am Coll Physicians Background: Benznidazole is effective for treating acute-stage Cha- gas disease,
but its effectiveness for treating indeterminate and chronic stages remains
uncertain. ... Objective: To compare long-term outcomes of patients with ... Cited by 93 - Related articles - BL Direct - All 7 versions
M van Rijnsoever, H Elsaleh, D Joseph, K … - Clinical Cancer Research, 2003 - AACR Purpose: The CpG island methylator phenotype (CIMP) is observed in approximately
30% of colorectal cancer (CRC) cases and is characterized by the concurrent
methylation of multiple CpG islands in tumor DNA. This phenotype (CIMP+) is ... Cited by 88 - Related articles - BL Direct - All 4 versions
- ►ascopubs.org AI Neugut, AT Fleischauer, V Sundararajan, N … - Journal of Clinical Oncology, 2002 - jco.ascopubs.org PATIENTS AND METHODS: The linked Surveillance, Epidemiology, and
End-Results–Medicare database was used to identify 1,807 Medicare
beneficiaries 65 years of age with stage II or III rectal cancer who ... Cited by 84 - Related articles - BL Direct - All 7 versions
- ►ascopubs.org TJ Iwashyna, EB Lamont - Journal of Clinical Oncology, 2002 - jco.ascopubs.org PURPOSE: Although randomized controlled trials (RCTs) consistently show that
adjuvant fluorouracil (5-FU) extends the survival of patients with stage III
colon cancer, it is not yet known whether this benefit exists in ... Cited by 84 - Related articles - BL Direct - All 7 versions
